| Theresa M Richter, MD | |
|
10900 W Potter Rd, Wauwatosa, WI 53226-3424 | |
| (262) 787-6737 | |
| (262) 782-6040 |
| Full Name | Theresa M Richter |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 42 Years |
| Location | 10900 W Potter Rd, Wauwatosa, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093755902 | NPI | - | NPPES |
| 34115300 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 25406 (Wisconsin) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Great Lakes Anesthesia And Pain Specialists Sc | 2365598406 | 15 |
News Archive
The University of Minnesota Medical School continues its legacy of advancing cell replacement therapies with a scientific breakthrough that highlights the promise of cell therapies for muscular dystrophy.
GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the BEXXAR® therapeutic regimen.
Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
The National Nanotechnology Initiative (NNI) released today a Progress Review on the Coordinated Implementation of the National Nanotechnology Initiative 2011 Environmental, Health, and Safety Research Strategy, a document that demonstrates the wide range of research activities, accomplishments, and collaborations of Federal agencies working toward the responsible development of nanotechnology.
› Verified 6 days ago
| Entity Name | Anex, S.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578510632 PECOS PAC ID: 4486540556 Enrollment ID: O20040225000719 |
News Archive
The University of Minnesota Medical School continues its legacy of advancing cell replacement therapies with a scientific breakthrough that highlights the promise of cell therapies for muscular dystrophy.
GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the BEXXAR® therapeutic regimen.
Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
The National Nanotechnology Initiative (NNI) released today a Progress Review on the Coordinated Implementation of the National Nanotechnology Initiative 2011 Environmental, Health, and Safety Research Strategy, a document that demonstrates the wide range of research activities, accomplishments, and collaborations of Federal agencies working toward the responsible development of nanotechnology.
› Verified 6 days ago
| Entity Name | Brookfield Anesthesiologists Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942257902 PECOS PAC ID: 5395847529 Enrollment ID: O20070219000542 |
News Archive
The University of Minnesota Medical School continues its legacy of advancing cell replacement therapies with a scientific breakthrough that highlights the promise of cell therapies for muscular dystrophy.
GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the BEXXAR® therapeutic regimen.
Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
The National Nanotechnology Initiative (NNI) released today a Progress Review on the Coordinated Implementation of the National Nanotechnology Initiative 2011 Environmental, Health, and Safety Research Strategy, a document that demonstrates the wide range of research activities, accomplishments, and collaborations of Federal agencies working toward the responsible development of nanotechnology.
› Verified 6 days ago
| Entity Name | Great Lakes Anesthesia And Pain Specialists Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720218647 PECOS PAC ID: 2365598406 Enrollment ID: O20090915000534 |
News Archive
The University of Minnesota Medical School continues its legacy of advancing cell replacement therapies with a scientific breakthrough that highlights the promise of cell therapies for muscular dystrophy.
GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the BEXXAR® therapeutic regimen.
Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
The National Nanotechnology Initiative (NNI) released today a Progress Review on the Coordinated Implementation of the National Nanotechnology Initiative 2011 Environmental, Health, and Safety Research Strategy, a document that demonstrates the wide range of research activities, accomplishments, and collaborations of Federal agencies working toward the responsible development of nanotechnology.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Theresa M Richter, MD 225 S Executive Dr, Brookfield, WI 53005-4257 Ph: (262) 787-6737 | Theresa M Richter, MD 10900 W Potter Rd, Wauwatosa, WI 53226-3424 Ph: (262) 787-6737 |
News Archive
The University of Minnesota Medical School continues its legacy of advancing cell replacement therapies with a scientific breakthrough that highlights the promise of cell therapies for muscular dystrophy.
GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the BEXXAR® therapeutic regimen.
Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
The National Nanotechnology Initiative (NNI) released today a Progress Review on the Coordinated Implementation of the National Nanotechnology Initiative 2011 Environmental, Health, and Safety Research Strategy, a document that demonstrates the wide range of research activities, accomplishments, and collaborations of Federal agencies working toward the responsible development of nanotechnology.
› Verified 6 days ago
Craig R Cook, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4025 N 92nd St, Wauwatosa, WI 53222 Phone: 414-358-5431 Fax: 414-358-5421 | |
William Jonathan Wood, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2643 N 113th St, Wauwatosa, WI 53226 Phone: 414-526-9683 | |
Maryam K Doyle, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 10900 W Potter Rd, Wauwatosa, WI 53226 Phone: 414-774-9227 | |
Omar Dyara, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 959 N Mayfair Rd, Wauwatosa, WI 53226 Phone: 414-955-3955 | |
Dr. Shibani Bhattacharyya, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 11152 W Meinecke Ave, Apt #2, Wauwatosa, WI 53226 Phone: 804-878-0278 | |
Khalid Ghazi Al Abdul Raheem, B.S Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4025 N 92nd St, Wauwatosa, WI 53222 Phone: 414-358-5431 |